Role of chimerism monitoring and donor lymphocyte infusion in eliminating the risk of graft rejection following HSCT in thalassemia patients-review.
10.7534/j.issn.1009-2137.2013.05.054
- Author:
Zhan-Feng LI
1
;
Xin SUN
Author Information
1. Department of Pediatric Hematology, Guangzhou Women and Chirdren's Medical Center, Guangzhou 510623, Guangdong Province, China.
- Publication Type:Journal Article
- MeSH:
Graft Rejection;
etiology;
Humans;
Lymphocyte Transfusion;
Thalassemia;
therapy;
Tissue Donors;
Transplantation Chimera
- From:
Journal of Experimental Hematology
2013;21(5):1356-1360
- CountryChina
- Language:Chinese
-
Abstract:
One of the major obstacle for hematopoietic stem cell transplantation (HSCT) to treat patients with beta-thalassemia is graft rejection (GR). The proportion of donor-derived cells continually declined in mixed chimerism (MC), finally leading to graft failure. Monitoring chimerism after transplant consecutively can early find unstable mixed chimerism and rejection, which provide the basis for donor lymphocyte infusion (DLI); for imminent risk of graft rejection, escalating doses of DLI is a feasible method for converting unstable MC towards stable MC or full donor chimerism. This review focuses on advancement of chimerism monitoring and DLI after HSCT for patients with β-thalassemia major.
